Suggested remit: To appraise the clinical and cost effectiveness of burosumab within its marketing authorisation for treating X-linked hypophosphatemia (XLH) in adults
Status
|
In progress
|
Technology type
|
Medicine
|
Decision
|
Selected
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
Process |
TA
|
ID number |
3822
|
Project Team
Project lead |
Vonda Murray |
Email enquiries
Stakeholders
Companies sponsors |
Kyowa Kirin (burosumab) |
Others |
Health Technology Wales |
|
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
Metabolic Support UK |
|
XLH UK |
Professional groups |
Royal College of Physicians |
Assessment group |
Centre for Reviews and Dissemination and Centre for Health Economics – York |
Associated public health groups |
None |
Comparator companies |
A H Pharmaceuticals (alphacalcitriol) (confidentiality agreement not signed, not participating) |
|
Atnahs Pharma UK (calcitriol) (confidentiality agreement not signed, not participating) |
|
Sigma Pharmaceuticals (alphacalitriol) (confidentiality agreement not signed, not participating) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
|
Welsh Government |
Relevant research groups |
National Institute for Health Research |
Date
|
Update
|
29 November 2023 - 03 January 2024
|
Draft guidance |
08 November 2023
|
Committee meeting |
23 February 2023
|
Invitation to participate |
18 January 2023
|
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-February 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
11 July 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
11 July 2022
|
Topic selection. Change decision to selected |
08 July 2022
|
Topic selection |
07 January 2022
|
In progress. Scoping commenced |
09 December 2021
|
The topic was discussed at the Topic Selection Oversight Panel (TSOP) in October 2021. The panel concluded that the topic was suitable for a Technology Appraisal. Following conversations with the company, the scheduling of the evaluation is to be confirmed and stakeholders will be updated in due course. |
04 March 2021 (10:00)
|
Scoping workshop |
07 January 2021 - 04 February 2021
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual